There is something philosophically arresting about the possibility that one of the most significant advances in trauma resuscitation in recent years is, at its core, a return to what military surgeons were doing at the Battle of Cambrai in 1917. In that year, Captain Oswald Robertson of the US Army Medical Corps stored O-negative blood for up to fourteen days and transfused it directly to British casualties on the Western Front. It worked. By the Second World War, whole blood combined with freeze-dried plasma had become the backbone of forward surgical care. Then, gradually, it was abandoned - and trauma medicine spent the next half-century navigating the consequences of that decision. The current debate over whole blood versus balanced component therapy is not simply a pharmacological dispute about ratios and logistics. It is, in the deepest sense, a reckoning with where resuscitation science went wrong and how far it has come back.
For candidates sitting the ATLS exam, haemorrhagic shock and its management are among the highest-yield topics in the syllabus. Understanding not just the current recommendations but the contested evidence behind them is precisely what separates a candidate who has memorised protocols from one who can reason about trauma. This debate sits squarely in that territory.
How We Got Here: The Vietnam Pivot and Its Legacy
The shift from whole blood to component therapy began in earnest around the time of the Vietnam War in the early 1970s, driven by practical rather than clinical considerations. Separating blood into its constituent parts - packed red blood cells, fresh frozen plasma, and platelets - allowed better resource allocation, extended shelf lives for individual components, and reduced infectious disease transmission through the use of selective screening. The change was made without the support of randomised controlled trials or large observational studies comparing outcomes between the two approaches. Medicine accepted it as obvious, and moved on.
What followed was decades of resuscitation practice shaped by the new paradigm. For much of the late twentieth century, early trauma resuscitation was characterised by large volumes of crystalloid administered first, with blood components added later. The ATLS guidelines themselves once enshrined this sequence. The physiological consequences gradually became apparent: dilutional coagulopathy, hypothermia, and acidosis - the "lethal triad" - were being worsened rather than reversed by the standard of care. The survival of the most severely injured patients stagnated.
The counter-movement began, as so many trauma innovations do, in the military context. Combat experience in Iraq and Afghanistan, where evacuation times were short enough to allow coordinated blood product use at the point of injury, demonstrated that warm fresh whole blood - transfused directly from walking donors to casualties - was associated with markedly improved survival in haemorrhagic shock. A landmark 2009 analysis by Spinella and colleagues in the Journal of Trauma found that warm fresh whole blood was independently associated with improved survival in combat-related injuries compared with component therapy. The biological rationale is compelling: whole blood contains red cells, plasma, clotting factors, and functional platelets in their native physiological proportions, without the storage lesions or dilution effects that accrue when components are separated, stored, and later recombined.
The 1:1:1 Era and Its Discontents
The civilian trauma community's response to the military evidence was the development of damage control resuscitation, which attempted to approximate whole blood using balanced component therapy - packed red blood cells, fresh frozen plasma, and platelets transfused in a ratio of 1:1:1. The landmark PROPPR trial, published in JAMA in 2015, was a randomised controlled trial comparing 1:1:1 to 1:1:2 ratios in 680 patients with major haemorrhage at 12 North American Level I trauma centres. Patients receiving the 1:1:1 ratio had higher rates of haemostasis at 24 hours and lower 24-hour mortality, establishing the 1:1:1 approach as the evidential backbone of modern haemostatic resuscitation. The American College of Surgeons Committee on Trauma, the Eastern Association for the Surgery of Trauma (EAST), and the ATLS 10th and 11th editions all incorporated early balanced resuscitation with reduced crystalloid use into their guidelines.
But 1:1:1, as the physiologists pointed out, is not the same as whole blood. Recombined components lack the cellular and biochemical synergies of fresh blood, are subject to storage lesions, and require coordinated logistics to deliver simultaneously - a non-trivial challenge in the first chaotic minutes of trauma resuscitation. Crucially, observational data from both military and civilian settings consistently showed that, when whole blood was available, patients transfused with it received fewer total units, reached haemostasis faster, and in many analyses appeared to survive at higher rates than those receiving equivalent volumes of components. The question became increasingly urgent: was 1:1:1 merely the best available approximation of what we should actually be giving, and should the pendulum swing back further?
The 2024 Evidence: A Genuinely Contested Field
2024 produced a cluster of high-quality studies that crystallise exactly why this debate remains unresolved, and why it is the kind of problem that the ATLS exam increasingly tries to probe.
In December 2024, Dorken-Gallastegi and colleagues published a large retrospective cohort study in the Annals of Surgery, drawing on data from over 12,000 patients with a shock index greater than one across 501 US trauma centres in the American College of Surgeons Trauma Quality Improvement Program database. Whole blood resuscitation was associated with lower adjusted odds of 4-hour mortality (adjusted odds ratio 0.81, 95% CI 0.68–0.97), 24-hour mortality, and 30-day mortality compared with component therapy alone. Higher ratios of whole blood to total transfusion volume were associated with incrementally lower mortality. This is one of the largest real-world datasets ever assembled on the question.
Yet a 2024 single-centre retrospective cohort study published in the Journal of Trauma and Acute Care Surgery - a Level I centre that had adopted a whole-blood-first resuscitation paradigm in 2018 - found that whole blood was not independently associated with improved survival compared with balanced component therapy when both groups were receiving truly balanced 1:1:1 resuscitation. Unadjusted 24-hour and 30-day survival were equivalent. The authors' title captured the dilemma with unusual candour: Whole blood versus balanced resuscitation in massive haemorrhage: Six of one or half dozen of the other?
More recently still, a large statewide analysis using the Pennsylvania Trauma Outcomes Study registry, presented at the American College of Surgeons Clinical Congress 2024 and subsequently published, found that cold-stored whole blood resuscitation was associated with equivocal in-hospital outcomes and mortality when compared to properly balanced component therapy. The key variable, it appears, is not simply whether whole blood is used, but whether - in the component arm - a genuinely balanced 1:1:1 ratio with early plasma and platelet delivery is achieved. When it is, the mortality benefit of whole blood may be substantially reduced or eliminated. When it is not - which is common in practice, because logistical constraints frequently delay balanced component delivery - whole blood's advantage re-emerges.
The ACS Committee on Trauma has nonetheless continued to advocate strongly for expanded whole blood access, particularly in the prehospital setting. At the ACS Clinical Congress 2024, Jeffrey Kerby, Chair of the Committee on Trauma, stated that prehospital blood access could potentially prevent up to 10,000 deaths per year in the United States. The Committee is actively pursuing policy changes to make prehospital whole blood universally available.
The EAST Guideline and the Unresolved RCT Question
EAST - the Eastern Association for the Surgery of Trauma, whose practice management guidelines sit alongside ATLS recommendations as core references in North American trauma - published a formal systematic review and practice management guideline on whole blood resuscitation in 2024. Covering 21 studies published between 2013 and 2023, the review concluded with a conditional recommendation in favour of whole blood over component therapy alone to decrease mortality, while acknowledging that the only randomised controlled trial included - a small pilot by Cotton and colleagues involving 107 patients - demonstrated no statistically significant difference in 24-hour or 30-day mortality on univariate analysis, though sensitivity analyses showed reduced transfusion requirements with whole blood in patients without severe traumatic brain injury.
The word conditional matters here. In GRADE methodology, a conditional recommendation means the evidence does not yet support universal application: benefits are likely but the certainty is low, and the balance between benefits and harms depends on individual circumstances. The principal concerns are practical as well as clinical. Alloimmunisation is a genuine safety consideration: Rh-negative women of childbearing age who receive Rh-positive low-titre group O whole blood may develop anti-D antibodies, creating haemolytic disease risk in future pregnancies. This was a central point of debate at the ACS 2024 session on whole blood, and it is a concern that the military context - where the majority of casualties are male - does not adequately surface. Blood wastage is a related logistical challenge, given that cold-stored whole blood has a shorter practical window of use than separated components, and trauma activations do not always result in massive transfusion.
The definitive RCT - the WEBSTER trial, currently under way - is designed to resolve the core mortality question: modified whole blood compared to balanced component therapy in haemorrhagic shock, with 28-day mortality and organ dysfunction as primary outcomes. Until WEBSTER reports, the evidence base will remain what it is: suggestive, internally contested, and methodologically dominated by retrospective observational data subject to survivor bias and confounding.
The ATLS Perspective: What Has Changed and Why It Matters
For ATLS candidates, several concrete evolutions in guidance are directly examinable and clinically important.
The ATLS 11th Edition, published in 2023, marked a significant departure from earlier crystalloid-dominated algorithms. The recommendation to limit initial crystalloid resuscitation to no more than one litre, with early transition to blood products, reflects the accumulated evidence that high-volume crystalloid resuscitation is independently associated with mortality. The xABCDE framework, with haemorrhage control elevated to the first priority in the approach to the severely injured patient, similarly reflects the paradigm shift away from airway-first sequencing in the actively bleeding patient.
The question of whole blood per se is not yet a formal part of the core ATLS algorithm - which continues to recommend 1:1:1 component therapy as the haemostatic resuscitation standard. But the clinical reasoning behind the whole blood debate maps precisely onto the core concepts that the exam tests: understanding the lethal triad of coagulopathy, acidosis, and hypothermia; understanding why 1:1:1 approximates physiological blood composition; understanding why early and simultaneous delivery of all blood components matters more than the total volume; and understanding the patient populations in whom certain transfusion strategies carry specific risks.
The broader story - that trauma resuscitation moved away from whole blood for logistical reasons without RCT evidence, spent decades accumulating data on the harms of that decision, and is now returning to whole blood through a combination of military experience and improving civilian logistics - is also a story about how evidence evolves in trauma care. Unlike many fields, trauma does not lend itself easily to randomised trials. The most consequential changes in resuscitation practice over the past century have been driven by observational data, military necessity, and physiological reasoning - with RCT confirmation arriving, if at all, years or decades later. The PROPPR trial itself was exceptional precisely because it was an RCT in trauma haemorrhage. WEBSTER will be another.
For the clinician standing over a haemorrhaging patient in a well-resourced centre with cold-stored whole blood in the fridge, the current evidence supports its use, with awareness of the alloimmunisation risk in Rh-negative women of childbearing age. For the clinician in a system without whole blood access, achieving a truly balanced 1:1:1 component resuscitation, as rapidly as possible, remains the evidence-based standard. The lesson that cuts across both contexts is older than either debate: crystalloid is not a substitute for blood, and the body haemorrhaging from trauma needs, above all else, to be given back something that resembles what it has lost.
